Center for Reproductive Medicine, Department of Obstetrics and Gynaecology (H4-205), Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands;
Int J Womens Health. 2010 Aug 9;1:205-11. doi: 10.2147/ijwh.s4729.
Anovulation is a common cause of female subfertility. Treatment of anovulation is aimed at induction of ovulation. In women with clomiphene-citrate resistant WHO group II anovulation, one of the treatment options is ovulation induction with exogenous follicle-stimulating hormone (FSH or follitropin). FSH is derived from urine or is produced as recombinant FSH. Two forms of recombinant FSH are available - follitropin alpha and follitropin beta. To evaluate the efficacy, safety, costs and acceptability of recombinant FSH, we performed a review to compare recombinant FSH with urinary-derived FSH products. Follitropin alpha, beta and urinary FSH products appeared to be equally effective in terms of pregnancy rates. Patient safety was also found to be comparable, as the incidence of side effects including multiple pregnancies was similar for all FSH products. In practice follitropin alpha and beta may be more convenient to use due to the ease of self-administration, but they are also more expensive than the urinary products.
排卵障碍是女性不孕的常见原因。排卵障碍的治疗旨在诱导排卵。对于氯米酚 citrate 耐药的 WHO Ⅱ型排卵障碍患者，治疗选择之一是使用外源性卵泡刺激素（FSH 或 follitropin）诱导排卵。FSH 来源于尿液或作为重组 FSH 产生。有两种形式的重组 FSH - follitropin alpha 和 follitropin beta。为了评估重组 FSH 的疗效、安全性、成本和可接受性，我们进行了一项综述，比较了重组 FSH 与尿源性 FSH 产品。在妊娠率方面，follitropin alpha、beta 和尿源性 FSH 产品似乎同样有效。患者安全性也相当，因为所有 FSH 产品的副作用发生率（包括多胎妊娠）相似。在实践中，由于易于自我给药，follitropin alpha 和 beta 可能更方便使用，但它们比尿源性产品更昂贵。
